Clinical trials: Myotonic Dystrophy Type 2
Myotonic Dystrophy 1, Myotonic Dystrophy 2
Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study
The natural history of brain affection in myotonic dystrophy types 1 and 2 is still unknown. The investigators designed a 5-year longitudinal neuropsychological and neuroimaging follow-up study to address this issue.
- Trial name
- NCT02729597
- Testing
- medical history, neurological clinical examination, neuropsychological testing
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Diabetes Mellitus
Improving Glycemic Control With Telemedicine and Smart Insulin Pens
Almost 40% of veterans have diabetes, the proposed research may improve clinical care among veterans with diabetes. In this application we are going to examine whether utilizing Smart Insulin pens (SIPs) with CGMs and…
- Trial name
- NCT06918977
- Testing
- InPen Smart insulin pen, traditional/standard insulin pen
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Maryland, Baltimore
Non Invasive Prenatal Diagnosis
NIPD on CFTC for Triplet Repeat Diseases
The purpose of this study is to develop and validate an analytical and clinical NIPD test for triplet repeat diseases by isolated circulating fetal trophoblastic cells (CFTC) analysis from maternal blood, searching for the…
- Trial name
- DIACCIMEX (NCT03087526)
- Testing
- Non invasive prenatal diagnosis
- Where
- 8 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Myotonic Dystrophy Type 2, Myotonic Dystrophy Type 1
Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2
Nearly two-third of patients with myotonic dystrophy type 2 (DM2) report that impaired cognition is among the most disabling symptoms and deeply affects their quality of life.
- Trial name
- BraCE-DM2 (NCT05854433)
- Testing
- Non-interventional study
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Dysautonomia
Autonomic Cardiovascular Neuropathy in Recently Diagnosed DM2 Patients (ACNDM2)
The investigators are studying the initial autonomic alterations in participants recently diagnosed with DM2 and in those patients classified as Pre-Diabetes, mainly focused on the baroreceptor sensitivity and on the peripheral…
- Trial name
- ACNDM2 (NCT02931773)
- Testing
- Task Force® Monitor
- Where
- Mexico
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Diabetes Mellitus, Type 2
Comparative Effectiveness of POC-A1c vs the Current Standard Based on OGTT for Early Detection DM2 in Colombia
Evaluate the impact of conducting a screening questionnaire (FINDRISC) and the implementation of a point-of-care HBA1c test for those with identified risk to suffer Diabetes in ten years, to improve the proportion of patients…
- Trial name
- EDDIT-1 (NCT05440968)
- Testing
- Point of Care - Glycated Hemoglobin (A1c), Oral Glucose Tolerance Test
- Where
- Colombia
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Humberto Reynales MD MSc PhD
Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2
Effect of CPAP on Myocardial Dysfunction in Type 2 Diabetes Mellitus and Obstructive Sleep Apnea Patients
This study evaluates the effect of the use of nasal CPAP in the cardiac function, measured by strain and TEI index, in patients with type 2 diabetes mellitus, obstructive sleep apnea and obesity.
- Conditions
- Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2, Continuous Positive Airway Pressure, Myocardial Dysfunction
- Trial name
- NCT03221205
- Testing
- Therapeutic CPAP
- Where
- Mexico
- Volunteers
- 78 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
Diabetes Mellitus, Type 2
Satisfaction With FreeStyle Libre 2 Monitoring Versus Capillary Blood Glucose Monitoring in People With DM2
The FreeStyle Libre 2 system is a Flash glucose monitoring system that, after a scan, provides information on interstitial glucose for the last 8 hours in the form of a reading every 15 min.
- Trial name
- Diabetes type2 (NCT06624553)
- Testing
- FreeStyle Libre 2, flash glucose monitoring
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Diabetes Mellitus, Hyperglycemia
CGM/Clarity Use, Glycemic Control and Clinical Outcomes
The prevalence of Diabetes Mellitus (DM) is rising and more than 30 million of Americans or 9.4% of the US population has DM. Several large scale randomized clinical trials have found that improved glycemic control reduces the…
- Conditions
- Diabetes Mellitus, Hyperglycemia, Hypoglycemia
- Trial name
- NCT03827434
- Testing
- Continuous glucose Monitoring Devices and Clarity Software, Point of Care (POC) blood glucose
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Myotonic Dystrophy 1, Myotonic Dystrophy 2
An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-up Period
This natural history observational study is being conducted to follow patients with DM1 or DM2 over a 2 year period to study the presence of myotonia, how it's perceived and its impact on patients quality of life.
- Trial name
- Track-DM (NCT07732439)
- Where
- 6 sites in France
- Volunteers
- 100 people
- Sponsor
- Lupin Ltd.
Myotonic Dystrophy
The United Kingdom National Registry for Myotonic Dystrophy
Myotonic dystrophy (dystrophia myotonica - DM) exists in two forms, usually referred to as DM1 (type 1) and DM2 (type 2). Both conditions are genetic disorders but each affects a different gene.
- Trial name
- NCT04003363
- Testing
- Patient Registry
- Where
- United Kingdom
- Volunteers
- 900 people
- Sponsor
- Newcastle University
Diabetes
Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen
The aim of the TELESAGE study is to demonstrate 1. the superiority of follow up with the DIABEO system (software alone) versus usual follow up in terms of improvement in HbA1c after 1 year in DM1 or DM2 patients treated with a…
- Trial name
- TELESAGE (NCT02287532)
- Testing
- DIABEO software
- Where
- 108 sites in France
- Volunteers
- 667 people
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Diabetes Mellitus, Type 2, Hypercholesterolemia
Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)
Objective: To investigate the effect of 5 weeks dapagliflozin 10 mg once daily treatment on glucose and lipid fluxes in patients with type 2 diabetes. Study design: Single center single arm (mechanistic) intervention trial.
- Trial name
- DICE (NCT03074630)
- Testing
- Dapagliflozin, Rosuvastatin
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Amsterdam UMC, location VUmc
Impaired Blood Glucose Level, Overweight
Early Diagnosis of Diabetes Mellitus Type 2 (DM2)
Rationale: The global prevalence of diabetes, along with its devastating effects on life expectancy and quality of life, continues to increase.
- Conditions
- Impaired Blood Glucose Level, Overweight, Obesity
- Trial name
- 7348 (NCT00469287)
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- TNO
Diabetes Mellitus, Type 2
Lifestyle Advises Sent Via Email in Attempt of Improving A1C in DM2 Patients
Diabetic patients need to manage their glucose level, physical activity and food intake to successfully cope with their disease.
- Trial name
- NCT03168633
- Testing
- web-based DM2 information pages
- Volunteers
- 50 people
- Sponsor
- Rambam Health Care Campus
Diabetes Mellitus
Improving Glycemic Control in DM2 Patients in the Ambulatory Setting
More than 10.5% of the US population has diabetes mellitus. The objective of this pilot study is to evaluate whether smart insulin pens combined with CGM devices can improve glucose control in patients with type 2 diabetes (T2D)
- Trial name
- NCT04800471
- Testing
- Smart insulin pens and CGM, Point of Care Glucose Group
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Myotonic Dystrophy Type 1 and Type 2
Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 [The MIND Study]
- Trial name
- MIND (NCT04700046)
- Testing
- Mexiletine 167 mg
- Sponsor
- Lupin Ltd.
Diabetes Mellitus, Tuberculin (Skin Test) Positive
Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)
Researchers will evaluate the efficacy, toxicity, adherence and cost effectiveness of treatment with isoniazid or rifampicin in patients with diabetes mellitus type two (DM2) and latent TB (LTB).
- Trial name
- TBL (NCT03278483)
- Testing
- Isoniazid 300 mg Oral Tablet, Rifampin 600 mg Oral Tablet
- Where
- Mexico
- Volunteers
- 396 people
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
Severe Obesity, Type 2 Diabetes Mellitus in Obese
L-Cell Activity in Small Intestine as Biliopancreatic Loop in Obese Patients With DM2 Submitted to RYGBP
Prevalence of Obesity and its association with Diabetes Mellitus 2 (DM2) affect a significant percentage of the world's population with great socioeconomic impact, especially for developing countries.
- Trial name
- NCT05446415
- Testing
- Analyze basal expression incretin for immunolabeling and mRNA expression glucagon-like secretion peptide-1 (GLP-1) and peptide YY (PYY 3-36) incretins by L cells.
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Dystrophia Myotonica 1
Methylphenidate in Myotonic Dystrophy Type 1
The purpose of this study is to determine whether methylphenidate is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).
- Trial name
- NCT01421992
- Testing
- Methylphenidate
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- Laval University